Bojarska-Junak A - Search Results

1

Assessment of peripheral blood and bone marrow cells apoptosis caused by purine analogues in patients with chronic lymphocytic leukemia in correlation with parameters of disease progression.

Podhorecka M, Klimek P, Kowal M, Chocholska S, Bojarska-Junak A, Dmoszynska A. Podhorecka M, et al. Acta Haematol. 2010;123(3):171-8. doi: 10.1159/000294961. Epub 2010 Mar 11. Acta Haematol. 2010. PMID: 20224269

2

[CD43 in B-cell chronic lymphocytic leukemia].

Roliński J, Rupniewska ZM, Dmoszyńska A, Wasik-Szczepanek E, Bojarska-Junak A. Roliński J, et al. Pol Arch Med Wewn. 1999 Sep;102(3):753-62. Pol Arch Med Wewn. 1999. PMID: 10949882 Review. Polish.

3

Influence of thalidomide on Bcl2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients.

Dmoszyńska A, Roliński J, Bojarska-Junak A, Mańko J, Jawniak D, Walter-Croneck A, Soroka-Wojtaszko M, Hus M. Dmoszyńska A, et al. Pol J Pharmacol. 2001 Nov-Dec;53(6):709-13. Pol J Pharmacol. 2001. PMID: 11985351 Free article.

4

Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.

Dmoszyńska A, Bojarska-Junak A, Domański D, Roliński J, Hus M, Soroka-Wojtaszko M. Dmoszyńska A, et al. Leuk Lymphoma. 2002 Feb;43(2):401-6. doi: 10.1080/10428190290006224. Leuk Lymphoma. 2002. PMID: 11999576

5

Intracellular tumor necrosis factor production by T- and B-cells in B-cell chronic lymphocytic leukemia.

Bojarska-Junak A, Rolinski J, Wasik-Szczepaneko E, Kaluzny Z, Dmoszynska A. Bojarska-Junak A, et al. Haematologica. 2002 May;87(5):490-9. Haematologica. 2002. PMID: 12010662

6

The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma.

Dmoszynska A, Podhorecka M, Manko J, Bojarska-Junak A, Rolinski J, Skomra D. Dmoszynska A, et al. Neoplasma. 2005;52(2):175-81. Neoplasma. 2005. PMID: 15800717 Clinical Trial.

7

Modification of immunocytochemical ZAP-70 assay for potential clinical application in B-cell chronic lymphocytic leukemia.

Bojarska-Junak A, Roliński J, Kawiak J. Bojarska-Junak A, et al. Folia Histochem Cytobiol. 2005;43(1):19-23. Folia Histochem Cytobiol. 2005. PMID: 15871558

8

Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.

Hus I, Roliński J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J, Giannopoulos K, Dmoszyńska A, Schmitt M. Hus I, et al. Leukemia. 2005 Sep;19(9):1621-7. doi: 10.1038/sj.leu.2403860. Leukemia. 2005. PMID: 15990861 Clinical Trial.

9

The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia.

Hus I, Podhorecka M, Bojarska-Junak A, Roliński J, Schmitt M, Sieklucka M, Wasik-Szczepanek E, Dmoszyńska A. Hus I, et al. Ann Oncol. 2006 Apr;17(4):683-90. doi: 10.1093/annonc/mdj120. Epub 2006 Mar 8. Ann Oncol. 2006. PMID: 16524977 Free article.

10

Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.

Giannopoulos K, Li L, Bojarska-Junak A, Rolinski J, Dmoszynska A, Hus I, Greiner J, Renner C, Döhner H, Schmitt M. Giannopoulos K, et al. Int J Oncol. 2006 Jul;29(1):95-103. Int J Oncol. 2006. PMID: 16773189

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

99 results

Search Page

Filters